Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Journals » Journal of Pain Management » Volume 4 Issue 3 Articles » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Red Sea: Historical Significance, Properties and Economic Importance
$73.80
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire?
02.Spinal Cord Neural Plasticity in Chronic Pain and its Clinical Implication
03.Plasticity in Chronic Pain Syndromes: The Role of Neuroimaging
Notifications more
NotificationsNotify me of updates to Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire?
Tell A Friend
 
Tell someone you know about this product.
Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire? $45.00
Authors:  Marcello Trevisani and Arpad Szallasi
Abstract:
Preclinical research has recently uncovered new molecular mechanisms underlying the generation and transduction of pain, many of which represent opportunities for pharmacological intervention. Manipulating TRP (Transient Receptor Potential) channels on nociceptive neurons is a particularly attractive strategy in drug development in that it targets the beginning of the pain pathway. The vanilloid (capsaicin) receptor TRPV1 is a multifunctional channel involved in thermosensation (heat) and taste perception (e.g. peppers and vinegar). Importantly, TRPV1 also functions as a molecular integrator for a broad range of seemingly unrelated noxious stimuli. Indeed, TRPV1 is thought to be a major transducer of the thermal hyperalgesia that follows inflammation and/or tissue injury. Desensitization to topical TRPV1 agonists (e.g. capsaicin creams and patches) has been in clinical use for decades to alleviate chronic painful conditions like diabetic neuropathy. Currently, site-specific capsaicin and resiniferatoxin (an ultrapotent capsaicin analogue) injections are being evaluated as “molecular scalpels” to achieve permanent analgesia in cancer patients with chronic, intractable pain. In the last five years, a number of potent, small molecule TRPV1 antagonists have been advanced into clinical trials for the treatment of inflammatory, neuropathic and visceral pain. Some of these compounds have successfully passed Phase 1 safety and tolerability studies in healthy volunteers into Phase 2 studies to access efficacy in patients, whereas others showed worrisome unforeseen adverse effects (most important, hyperthermia and impaired noxious heat sensation placing the patient at risk for scalding injury) in men, prompting their withdrawal from the clinical trials. In this paper, we first give an overview of the clinical trials with TRPV1 agonists (that “reignite the fire”) and then summarize the current state of the field pertaining to the known TRPV1 antagonists (“quenching the fire”) in clinical development. 


Available Options:
Version:
Special Focus Titles
01.Looking Upwards: Stars in Ancient and Medieval Cultures
02.Iranians in the Minds of Americans
03.Gleanings in the West of Ireland: Annotated Edition
04.Cystic Tumors of the Pancreas
05.Normalization, Enjoyment and Bodies/Emotions: Argentine Sensibilities
06.Genius, Creativity and Madness
07.The New Age of the Confederacy: Trump and the Surge in National Disunity
08.Social Media: Practices, Uses and Global Impact
09.The Wetlands of India
10.Geomagnetosphere and Coupling Phenomena, Volume I: Solar Wind/IMF Coupling with Geomagnetosphere/Ionosphere
11.Turbochargers and Turbocharging: Advancements, Applications and Research
12.Completion and Unification of Quantum Mechanics with Einstein's GR Ideas, Part II: Unification with GR

Nova Science Publishers
© Copyright 2004 - 2017

Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire?